妊娠期高血壓疾病課件_第1頁(yè)
妊娠期高血壓疾病課件_第2頁(yè)
妊娠期高血壓疾病課件_第3頁(yè)
妊娠期高血壓疾病課件_第4頁(yè)
妊娠期高血壓疾病課件_第5頁(yè)
已閱讀5頁(yè),還剩44頁(yè)未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

HypertensiveDisorders

inPregnancyTengYinChengShanghaiJiaotongUniversityAffiliatedSixthPeople'sHospital,DeptofObs&GynContentsEtiology&PathogenesisClinicalfeaturesPhysiopathologyClassificationDiagnosisManagement234561IncidenceandRiskFactorsIncidenceCommonlyabout5percentMarkedlyinfluencedbyparityRelatedtoraceandethnicity—AgeneticpredispositionMainRiskFactorsNulliparous(初產(chǎn)婦)MultiplepregnancyHistoryofchronichypertensionMaternalageover35yearsObesityLowersocioeconomicstatus…EtiologyandPathogenesisNormal:vesselremodeling(血管重鑄)ofthedeciduaandmyometriumtransformingintolarge-capacitance,low-resistancevesselsPreeclampsia:incompleteremodelinglimitedtothe

superficialdeciduamyometrialsegmentsremain

narrowFaultyPlacentation(胎盤形成不良)---StageIPathogenesisofpreeclampsiaGeneticfactorsimmunologicalfactorsMaternalvasculardiseaseEnvironmentalfactorsReduceduteroplacentalperfusionFaultyplacentationEndothelialactivationSystemicvasculardysfunctionCapillaryleakvasospasmHypertensionCerebraledema(eclampsia)EdemaProteinuriaCoagulationabnormalities(HELLP)Fetalgrowthrestriction(FGR)Physiopathology

------sgageII

Basicchange:SystemVasospasm(全身小動(dòng)脈痙攣)Hemorrhage,edema,hyperemia充血,thrombosis

Visualdisturbances:blurredvision,blindness,retinaldetachment(視網(wǎng)膜脫落)Reducedrenalperfusionandglomerularfiltration腎小球?yàn)V過(guò)率

Proteinuria;increaseduricacid;oliguriaIschemia,edema→elevatedserumtransaminases(ALT,AST,AKP..);jaundice(黃疸)Subcapsularhematoma(肝包膜下出血)orhepaticrupturePhysiopathologyPeripheralvascularresistance↑,cardiacoutput↓(低排高阻),bloodpressure↑Cardiacfailure(心力衰竭),pulmonaryedema(肺水腫)

Bloodvolume↓,hematocrit↑(HCT,紅細(xì)胞壓積)

,bloodconcentration

Hypercoagulability(高凝),thrombocytopenia(血小板減少)PlacentalischemiaandhypoxiaHigh-resistancecircuitwithdecreasedbloodFetalgrowthrestriction,fetaldistress(胎兒窘迫)WHATLINKSSTAGE

1&2?Theoryexploration:Genetics/AbnormallipidmetabolismEndocrinedysfunctionInflammationNotallwomenwithreducedplacentalperfusiondeveloppreeclampsia…

Whatlinksstages1and2?Reducedplacentalperfusionmustinteractwithmaternalfactorstoresultinpreeclampsia.Stage1???Stage2Roberts,J.M.,GammillH.S.(2005)Diversemanifestationsarepossible:maternalandfetal/placentalfactorsmayvaryinproportion.

Inawomanwithmany

predisposingfactors,evenaminorreductioninplacentalperfusionissufficientforstage2todevelop.Inawomanwithfewpredisposingfactors,aprofoundreductioninplacentalperfusionmayberequiredforpreeclampsiatodevelop.

Roberts,J.M.,GammillH.S.(2005)PredisposingfactorsReducedplacentalperfusionMicrosoftOffice2000Whatdoweknow?Weknowthatabnormalitiesinlipidmetabolismhaveageneticbasis.Wehavelearnedthatpreeclampsiaischaracterizedbyprofoundlipidabnormalitiessuchashypertriglyceridemia…Gratacos,E.(2000)MicrosoftOffice2000Couldabnormallipidmetabolismbeageneticfactorlinkingthestagesofpreeclampsia?

Stage1Stage2AbnormallipidmetabolismPreeclampsiaischaracterizedbymetabolicabnormalitiessimilartothosepresentinatherosclerosis:HypertriglyceridemiaReducedHDLcholesterolPredominanceofsmall-denseLDLcholesterolwhichhaveanincreasedpotentialtocauseendothelialcelldamageascomparedtolarger,morebuoyantLDL’s.GratacosE.,2000.Mostofthesuggestedlinkagescouldcontributetoorbestimulatedbyoxidativestress.Oxidativestressisproposedasrelevanttomanydiseases.Evidencesupportsthepresenceofoxidativestressinpreeclampsia:ProteinproductsofoxidativestresspresentinmaternalandfetaltissuesAntibodiestooxidativelymodifiedLDL’spresentinmaternalandfetaltissuesConcentrationsofcertainantioxidantsreducedinpreeclampticwomen.

Roberts,J.M.,GammillH.S.(2005)Insummary:Hypertriglyceridemiaandpredominanceofsmall-denseLDL’spriortopregnancycouldbeonepredisposingfactorfordevelopingpreeclampsia.Oxidativestressandinflammation maytriggerthematernaldisease.GratacosE.,(2000)MicrosoftOffice2000CouldendocrinedysfunctionbeafactorlinkingStage1andStage2?Stage1Stage2EndocrinedysfunctionStudieshaverepeatedlydemonstratedthatmetabolicabnormalitiesprecedetheclinicalsignsofpreeclampsia:InsulinresistanceandassociatedhyperinsulinemiaGlucoseintoleranceHypertriglyceridemiaThissuggeststhatinsulinresistanceanddyslipidemiamaybefactorsinvolvedinthedevelopmentofpreeclampsia.Innes,etal.(2005)Similaritiesbetweentheriskfactorsforpreeclampsiaandcardiovasculardiseaseinclude:InsulinresistanceDyslipidemia-decreasedHDLlevelsand elevatedtriglyceridelevelsTheseriskfactorsarethoughttoplayacausalroleinthedevelopmentofendothelialdysfunction,acharacteristicfeatureofpreeclampsiaandcardiovasculardisease.Innes,etal.(2005)“Preeclampsiaisassociatedwithanexcessiveinflammatoryresponsecomparedwithnormalpregnancy.”InastudydonebyBraekke,et.al(2005)inflammatorymarkers(calprotectin,CRP)wereevaluatedinmaternalandfetalserumandamnioticfluid.Braekke,K.,Holthe,Ml,Harsem,N.,Fagerhol,M.,Staff,A.,2005InflammatoryMarkers:Calprotectin:IsaproteinreleasedbyactivatedneutrophilsC-reactiveprotein(CRP):IsaproteinproducedbytheliverProductionisstimulatedbyinflammatorycytokinesBraekke,K.et.al.(2005)MicrosoftOffice2000CalprotectinandC-reactiveprotein(CRP),markersofinflammation,areelevatedinpreeclampsia.Theconcentrationofcalprotectininthematernalplasmaofpreeclampticwomenwashigherthaninthecontrolgroup(normalpregnantwomen).NostatisticallysignificantdifferenceincalprotectinlevelswasnotedbetweenwomenwithmildandseverepreeclampsiaBraekke,K.etal.(2005)C-reactiveprotein:Hasbeenusedtoevaluatelow-gradeinflammationasacardiovascularriskfactor

Braekkeetal.2005MicrosoftOffice2000CRPlevelsinthematernalplasmaofpregnantwomen:Correspondtoalow-gradeinflammationinpreeclampsiaandinnormalpregnancy.

Braekkeetal.2005MicrosoftOffice2000Concentrationsofcalprotectininbotharterialandvenousumbilicalplasma,andamnioticfluidweremuchlowerthaninmaternalplasmaCRPlevelsinfetalcirculationwere1/100ofmaternalCRPlevels.Noinflammatoryresponsewasnotedinthefetalcirculation.Braekkeetal.2005Theoretically,“Calprotectinconcentrationscouldplayaroleinthepathophysiologyofpreeclampsiathroughaugmentedplacentalcelldeathorreducedtrophoblastinvasion(stage1)”Braekkeetal.2005Whatstimulatestheinflammatoryresponse(activatestheneutrophils)inpreeclampsia?Researchershavebeenunabletodeterminewhyorexactlywheretheneutrophilsbecomeactivated.Maternalorplacentafactorstriggeringmaternalinflammationdonotappeartobetransferredintothefetalcirculation.

Braekkeetal.2005Futureimplications:Furtherresearchisneededtoevaluatetheroleofcalprotectininpregnancyorpregnancycomplications.Willcalprotectinconcentrationsbeused topredictpreeclampsiabeforetheonsetofclinicalsymptomsorasamarkeroftheclinicallyestablisheddisease?

Braekkeetal.2005ClassificationGestationalHypertensionBP≥140/90

mmHgforfirsttimeduringpregnancyNoproteinuriaBPreturntonormal<12weeks’postpartumFinaldiagnosismadeonlypostpartum(產(chǎn)后)Preeclampsia

BP≥140/90mmHgafter20weeks’gestationProteinuria300mg/24hoursor≥1+dipstick

EclampsiaSeizuresthatcannotbeattributedtoothercausesinawomanwithpreeclampsiaClassificationPreeclampsiaSuperimposedonChronicHypertensionNew-onsetproteinuria≥300mg/24hoursinhypertensivewomenbutnoproteinuriabefore20weeks’gestationAsuddenincreaseinproteinuriaorbloodpressureorplateletcount<100×109/LChronicHypertensioninPregnancyBP≥140/90mmHgbeforepregnancyordiagnosedbefore20weeks’gestationOrHypertensionfirstdiagnosedafter20weeks’gestationandpersistentafter12weeks’postpartumDiagnosis

HistoryHypertensionProteinuriaEdemaAssistantexaminationDiagnosisofseverepreeclampsiaCentralnervoussystem:headache,visualchanges,comaSubcapsularhematomaorhepaticrupture:epigastricdiscomfortorpersistrightupperquadrantpainHepaticimpairment:elevatedhepaticenzymesSystolicpressure≥160mmHg,ordystolicpressure≥110mmHgThrombocytopenia:<100×109/LProteinuria:≥5g/24hoursOliguria:<500ml/24hours(少尿)CerebralvascularcomplicationsIntravascularhemolysis:anemia,jaundice,LDH↑(血管內(nèi)溶血)CoagulationdisordersFGR(胎兒生長(zhǎng)受限)orOligohydramnion(羊水過(guò)少)ManagementPrinciplesSedation(鎮(zhèn)靜)Antihypertension(降壓)Antispasm(解痙)Diuresis(利尿)TerminationofpregnancyManagementGeneralmanagementBedrestFrequentfetalandmaternalmonitoringSedationDiazepam(地西泮,安定)Hibemation(冬眠藥物)pathidine派替啶,chlorpromazine氯丙嗪promethazine異丙嗪ManagementAntispasm(解痙)

:Topreventseizures

Magnesiumsulfate(硫酸鎂)MechanismDoseregimenloadingdose:5g,5-10minutescontinuousinfusion:20-25g,1-2g/hourtotaldailydose:25-30

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論